Neurosyphilis

The VDRL Test For Syphilis (Venereal Disease Research Laboratory) is a Class II medical device (FDA-cleared) non-treponemal flocculation test for qualitative and quantitative detection of reaginic antibodies in serum or cerebrospinal fluid, used for syphilis screening, diagnosis, and treatment monitoring. The test uses an antigen mixture (cardiolipin, cholesterol, lecithin) that reacts with antibodies, forming visible clumping (flocculation) in positive samples. Results are reported as reactive/non-reactive with quantitative titers (e.g., 1:2 to 1:256). Primary clinical applications include initial screening for syphilis infection, confirmation of active syphilis (with treponemal tests), monitoring treatment response (fourfold titer decrease indicates cure), diagnosis of neurosyphilis (CSF testing), prenatal screening for congenital syphilis prevention, screening in high-risk populations (MSM, HIV-positive, multiple partners), and blood donor screening. Critical safety precautions include confirmation of all reactive results with treponemal tests (TPPA, FTA-ABS), awareness of false positives (pregnancy, autoimmune disease, viral infections), proper specimen handling (universal precautions), refrigerated storage of reagents (2-8°C), and mandatory reporting of reactive results to public health authorities. Essential test for syphilis control and congenital syphilis prevention worldwide.